Literature DB >> 8070926

In vitro susceptibility and sterol biosynthesis of Candida albicans strains after long-term treatment with azoles in HIV-infected patients.

W Hundt1, H Hofmann.   

Abstract

Over a period of 6 to 24 months a long term follow up of the in vitro antifungal susceptibility of 306 Candida albicans strains from 49 HIV-infected patients was performed. Using a microdilution test, the strains were tested against the azoles ketoconazole, itraconazole and fluconazole. The susceptibility range for fluconazole was between 1 and 128 mg/l, for itraconazole between 0.015 and 32 mg/l and for ketoconazole between 0.007 and 16 mg/l. 11.7% of the strains showed elevated IC30-values against ketoconazole, 9.1% against itraconazole and 10.1% against fluconazole. Sterol biosynthesis was examined by thin layer chromatography in 18 less sensitive strains and nine sensitive strains in the presence of ketoconazole. The proportion of ergosterol in the presence of ketoconazole at a concentration of 0.003 mg/l varied between 7.6% and 21.1% in sensitive strains and between 11.1% and 86.6% in less sensitive strains. In resistant control strains the proportion of ergosterol was 73% and 94.2%, respectively. Without ketoconazole the ergosterol proportion was > 85% in all strains. There was a significant correlation between the IC30-values and the inhibition of ergosterol biosynthesis (p = 0.05).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8070926     DOI: 10.1007/bf01739023

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  23 in total

1.  Modified response to ketoconazole of Candida albicans from a treatment failure.

Authors:  D W Warnock; E M Johnson; M D Richardson; C F Vickers
Journal:  Lancet       Date:  1983-03-19       Impact factor: 79.321

Review 2.  Antifungal susceptibility tests.

Authors:  J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

3.  In-vitro resistance to imidazole antifungals in Candida albicans.

Authors:  E M Johnson; M D Richardson; D W Warnock
Journal:  J Antimicrob Chemother       Date:  1984-06       Impact factor: 5.790

4.  Inhibition of sterol C14 demethylation by imidazole-containing antifungals.

Authors:  G W Pye; M S Marriott
Journal:  Sabouraudia       Date:  1982-12

5.  Laboratory evaluation of antifungal agents: a comparative study of five imidazole derivatives of clinical importance.

Authors:  F C Odds
Journal:  J Antimicrob Chemother       Date:  1980-11       Impact factor: 5.790

6.  Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients.

Authors:  C R Horsburgh; C H Kirkpatrick
Journal:  Am J Med       Date:  1983-01-24       Impact factor: 4.965

7.  In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis.

Authors:  H Van den Bossche; G Willemsens; W Cools; F Cornelissen; W F Lauwers; J M van Cutsem
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

8.  Differential effects of cholesterol and lanosterol on artificial membranes.

Authors:  P L Yeagle; R B Martin; A K Lala; H K Lin; K Bloch
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

9.  Microtiter broth dilution method for yeast susceptibility testing with validation by clinical outcome.

Authors:  M Radetsky; R C Wheeler; M H Roe; J K Todd
Journal:  J Clin Microbiol       Date:  1986-10       Impact factor: 5.948

10.  Opportunistic infections of the esophagus not responding to oral systemic antifungals in patients with AIDS: their frequency and treatment.

Authors:  F Parente; M Cernuschi; G Rizzardini; A Lazzarin; L Valsecchi; G Bianchi Porro
Journal:  Am J Gastroenterol       Date:  1991-12       Impact factor: 10.864

View more
  2 in total

Review 1.  Azole resistance in Candida.

Authors:  D W Denning; G G Baily; S V Hood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

2.  Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain.

Authors:  J V Martinez-Suarez; J L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.